Related Experiment Video
Updated: Dec 6, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib
Takakiyo Tatsumichi1, Hiroaki Tanaka1, Tomoya Okazaki2
1Department of Pharmacy, Kagawa University Hospital, Kagawa, Japan.
What Is Known And Objective:
Our objective is to report on a case of posterior reversible encephalopathy syndrome associated with pazopanib.
Case Description:
A 64-year-old patient with uterine sarcoma developed PRES 3 days after pazopanib was initiated. After the discontinuation of pazopanib, the symptoms of PRES improved.
What Is New And Conclusion:
The first report worldwide to describe a patient with uterine sarcoma experiencing PRES caused by pazopanib. Patients with uterine sarcoma may experience PRES, even in the early phase of pazopanib therapy.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Treatment Resistant Cancers
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
